Biogen Idec reports that the US Food and Drug Administration (FDA) has approved Plegridy (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis (RMS). Plegridy is a pegylated beta interferon approved for use in RMS and is dosed once every two weeks and can be administered subcutaneously with the Plegridy Pen, a new ready-to-use autoinjector or a prefilled syringe.

Plegridy received approval from the European Commission in July 2014.

Source: Biogen Idec